Edwards Lifesciences Leans Into Growth After Strong Quarter

Edwards Lifesciences Corp. ((EW)) has held its Q4 earnings call. Read on for the main highlights of the call.

Edwards Lifesciences’ latest earnings call struck a distinctly upbeat tone, with management emphasizing strong sales growth, accelerating transcatheter valve momentum, and rising confidence in its 2026 financial targets. While heavier spending, tax headwinds, and one‑off charges pressured earnings, executives framed these as strategic or temporary, arguing that long‑term growth drivers and margin expansion remain firmly intact.

Strong Q4 and Full-Year Sales Growth

Edwards posted Q4 sales of $1.57 billion, up 11.6% year over year, underscoring resilient demand across its key franchises. Full‑year sales grew 10.7%, giving the company solid momentum as it heads into 2026 and reinforcing management’s view that structural tailwinds in structural heart therapies remain strong.

TAVR Performance and Clinical Momentum

The TAVR franchise delivered Q4 global sales of $1.16 billion, rising 10.6% with procedures growing in the high single digits, supported by robust adoption of SAPIEN 3 Ultra Resilia. Management highlighted long‑term PARTNER 2 and PARTNER 3 durability data, early TAVR evidence including asymptomatic patients, and favorable European guideline changes as powerful, enduring catalysts for further penetration.

TMTT Segment Surge

The transcatheter mitral and tricuspid therapies (TMTT) segment was a standout, surging more than 40% in Q4 to $156 million and surpassing $500 million in revenue for the full year. Growth was fueled by strong uptake of PASCAL and EVOQUE, the FDA approval and early launch of SAPIEN M3, and rollout of NextGen PASCAL, all feeding into Edwards’ ambition to build a roughly $2 billion TMTT business by 2030.

Surgical Business Milestones

Surgical heart valve sales reached $254 million in Q4, up 2%, with full‑year growth of 4.3% pushing the franchise past $1 billion in annual revenue for the first time. Management pointed to encouraging one‑year MOMENTYS data showing 100% freedom from structural valve deterioration and the planned initial introduction of surgical LAAC later this year as key product and clinical milestones.

Profitability and Margin Discipline

Q4 adjusted gross margin came in at 78.3%, slightly below the prior year’s 79%, while adjusted operating margin was 23.7%, with the full‑year figure at 27%, reflecting controlled cost of goods despite stepped‑up investment. Looking ahead to 2026, Edwards guided to gross margin around 78%–79% and expects about 150 basis points of operating margin expansion in constant currency, with a path to 50–100 basis points of annual improvement thereafter.

Strong Balance Sheet and Capital Return

The company closed the year with roughly $3 billion in cash and cash equivalents, giving it ample financial flexibility for R&D, commercialization, and selective deals. Edwards also remained active in returning cash to shareholders, repurchasing just under $900 million of stock in 2025 and leaving about $2 billion of buyback authorization still available.

Patient Access and Clinical Engagement Initiatives

A central theme of the call was stepped‑up investment in patient access and clinical engagement, spanning partnerships such as the American Heart Association valve initiative and efforts to disseminate updated European guidelines. Management is also bolstering its field force to encourage earlier, guideline‑based treatment, positioning these initiatives as critical to expanding the addressable patient pool over the long term.

Adjusted EPS Pressure and One-Time GAAP Impact

Despite strong revenue, Q4 adjusted EPS landed at $0.58 and fell short of expectations as higher spending on access programs and a higher‑than‑anticipated tax rate weighed on earnings. GAAP EPS was $0.11, reflecting additional one‑time charges tied to the GennaValve acquisition that did not close and litigation costs, which management emphasized are non‑recurring in nature.

Step-Up in SG&A Spending

Selling, general, and administrative expense rose to $603 million in Q4, representing 38% of sales versus 35% a year earlier, a roughly $112 million year‑over‑year increase. Management linked the uptick mainly to accelerated investments in patient access, clinician education, and field resources, arguing these expenses should drive higher volumes and operating leverage over time.

Tax Rate Headwind

The company reported a quarterly tax rate of 29% including special items and 17.9% excluding them, both above internal expectations, with Pillar Two rules and country mix cited as key drivers. For 2026, Edwards expects its tax rate excluding special items to moderate into the 16%–19% range, which should support EPS growth as other profitability initiatives take hold.

One-Time Charges and M&A Setback

Earnings were also affected by charges related to the terminated GennaValve acquisition and associated litigation, highlighting a bump in Edwards’ external growth strategy. While these items introduced noise into GAAP results and some uncertainty around near‑term M&A execution, management framed them as discrete events rather than a shift in the company’s broader strategic direction.

Distributor Inventory Adjustment in Surgical Segment

Surgical growth in Q4 was further muted by an end‑of‑year inventory adjustment at a distributor‑managed market, with China cited as an example of such territories, limiting segment growth to 2%. Executives characterized this as a timing issue rather than a demand problem and maintained confidence in the underlying health of the surgical business.

Seasonality and 2026 Comparison Headwinds

Looking to 2026, management cautioned that growth is likely to be stronger in the first half, with tougher year‑over‑year comparisons and seasonal patterns creating a more challenging backdrop later in the year. This expected cadence means investors may see uneven quarterly performance even as Edwards targets full‑year metrics consistent with its long‑term growth framework.

Moderate Aortic Stenosis Opportunity Still Uncertain

Executives reiterated the potential of the PROGRESS trial in moderate aortic stenosis as a longer‑term upside driver but stressed that results are still pending and will be presented at a future cardiology meeting. As a result, the company is not yet baking moderate AS into near‑term forecasts, preferring to wait for data clarity before sizing the opportunity.

Impact of Competitor Exit on Market Share

Management acknowledged that some recent share gains were aided by a competitor’s exit in certain markets, noting that part of the lift reflects market dynamics rather than pure head‑to‑head displacement. Even so, Edwards believes many of those share gains will prove sticky, supported by its expanding product portfolio and strong clinical evidence base.

Guidance and Forward-Looking Outlook

For 2026, Edwards reaffirmed and expressed greater confidence in its outlook for 8%–10% sales growth and adjusted EPS of $2.90–$3.05, supported by stable margins and FX expected to add about $40 million to revenue. Near term, Q1 sales are projected at $1.55–$1.63 billion with adjusted EPS of $0.70–$0.76, implying mid‑teens growth at the midpoint, as the company balances elevated investment with a goal of expanding operating margins by around 150 basis points.

Edwards Lifesciences’ earnings call painted the picture of a company leaning into growth, accepting near‑term earnings pressure in exchange for expanding its structural heart footprint. With robust TAVR and TMTT trends, a growing surgical franchise, a strong balance sheet, and clear margin expansion plans, management argued that the long‑term investment case remains compelling despite short‑term volatility in EPS and quarterly cadence.